Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, Loupakis F, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biagetti S, Menzo S, Falcone A, Bearzi I, Cascinu S. Scartozzi M, et al. Among authors: giampieri r. Int J Cancer. 2010 Oct 15;127(8):1941-7. doi: 10.1002/ijc.25193. Int J Cancer. 2010. PMID: 20099280
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.
Scartozzi M, Bearzi I, Mandolesi A, Giampieri R, Faloppi L, Galizia E, Loupakis F, Zaniboni A, Zorzi F, Biscotti T, Labianca R, Falcone A, Cascinu S. Scartozzi M, et al. Among authors: giampieri r. Br J Cancer. 2011 May 24;104(11):1786-90. doi: 10.1038/bjc.2011.161. Epub 2011 May 10. Br J Cancer. 2011. PMID: 21559018 Free PMC article.
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, Loupakis F, Falcone A, Bearzi I, Cascinu S. Scartozzi M, et al. Among authors: giampieri r. Ann Oncol. 2012 Jul;23(7):1706-12. doi: 10.1093/annonc/mdr558. Epub 2011 Nov 23. Ann Oncol. 2012. PMID: 22112971 Free article.
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, Galizia E, Loretelli C, Belvederesi L, Bittoni A, Cascinu S. Scartozzi M, et al. Among authors: giampieri r. Br J Cancer. 2012 Feb 28;106(5):799-804. doi: 10.1038/bjc.2012.17. Epub 2012 Feb 7. Br J Cancer. 2012. PMID: 22315053 Free PMC article.
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Scartozzi M, Bianconi M, Faloppi L, Loretelli C, Bittoni A, Del Prete M, Giampieri R, Maccaroni E, Nicoletti S, Burattini L, Minardi D, Muzzonigro G, Montironi R, Cascinu S. Scartozzi M, et al. Among authors: giampieri r. Br J Cancer. 2013 Mar 19;108(5):1126-32. doi: 10.1038/bjc.2012.501. Epub 2012 Nov 29. Br J Cancer. 2013. PMID: 23511629 Free PMC article.
122 results